* Theratechnologies to move forward with development of new
single vial formulation for EGRIFTA(R)(Tesamorelin for
injection)
Source text for Eikon:
Further company coverage:
The post BRIEF-Theratechnologies to move forward with development of new single vial formulation for EGRIFTA appeared first on NASDAQ.